Coherence Neuro Raises $45M to Develop Cancer Treatment

The big picture: San Francisco-based Coherence Neuro has raised $45 million in a Series A round co-led by Founders Fund and the OpenAI Startup Fund. The funding will support the development of technology designed to continuously monitor cancer and adjust treatment based on real-time biological signals, aiming to help physicians assess treatment effectiveness between conventional scans and blood tests.

Why it matters:

• Monitoring gaps: Current cancer monitoring relies on periodic imaging and lab tests, leaving significant intervals where physicians lack real-time data on tumor response, potentially delaying treatment adjustments.
• Early insights: Coherence Neuro’s approach seeks to provide continuous, granular data on tumor activity, potentially enabling earlier detection of treatment efficacy or progression than traditional methods.
• Personalized therapy: By combining biological sensing with computational models and electrical stimulation, the technology aims to create a system that could adapt treatment to a patient’s evolving condition, moving towards more personalized oncology.

How it works:

• Electrical biomarkers: The company’s core technology centers on identifying electrical biomarkers of cancer, hypothesizing that tumors alter electrical signals in surrounding tissue and the nervous system in detectable patterns.
• Implantable devices: Coherence Neuro is developing implantable devices that record these electrical signals, which are then analyzed by machine-learning models to estimate tumor growth or response to treatment.
• Combined approach: Beyond monitoring, the company intends to integrate electrical stimulation, creating devices capable of both measuring tumor-associated activity and delivering targeted therapeutic interventions.

The catch: Developing and commercializing implantable medical devices, particularly for oncology, faces significant regulatory hurdles and lengthy clinical trial processes. The translation of preclinical findings from animal models to human efficacy and safety is complex, and the market for advanced cancer monitoring is highly competitive, with numerous companies pursuing various diagnostic and therapeutic innovations. Proving the clinical utility and cost-effectiveness of a novel, invasive monitoring system will be critical for adoption.

Key Facts

• Company: Coherence Neuro
• Amount: $45M
• Round: Series A
• Investors: Founders Fund and OpenAI Startup Fund (co-lead), Lux Capital, 8VC, Timeless, Olive Capital, Ahren
• Founder: Ben Woodington
• Sector: Oncology Neurotechnology
• Headquarters: San Francisco, US